AUPH Stock Summary and Trading Ideas (Aurinia Pharmaceuticals - Common Shares | NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol AUPH.

As of January 27, 2026, AUPH stock price declined to $14.57 with 713,710 million shares trading.

AUPH has a beta of 0.18, meaning it tends to be less sensitive to market movements. AUPH has a correlation of 0.01 to the broad based SPY ETF.

AUPH has a market cap of $1.92 billion. This is considered a Small Cap stock.

Last quarter Aurinia Pharmaceuticals - Common Shares reported $73 million in Revenue and $.23 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.07.

In the last 3 years, AUPH traded as high as $16.54 and as low as $4.71.

The top ETF exchange traded funds that AUPH belongs to (by Net Assets): IWM, IWO, IBB, VTWO, JSMD.

AUPH has outperformed the market in the last year with a return of +82.1%, while the SPY ETF gained +15.6%. In the last 3 month period, AUPH beat the market returning +22.5%, while SPY returned +3.0%. However, in the most recent 2 weeks AUPH has underperformed the stock market by returning -4.6%, while SPY returned 0.0%.

AUPH support price is $14.40 and resistance is $15.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUPH shares will trade within this expected range on the day.